Related Experiment Video
Updated: May 2, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab
Rita Abdulkader1, Chethana Dharmapalaiah, Ginny Rose
1From the Research and Development Department, Department of Rheumatology, The Ipswich Hospital NHS Trust, Ipswich, UK.
Objective:
Late-onset neutropenia (LON) is an adverse effect of rituximab (RTX) in hematological malignancies, a finding that was recently reported in rheumatoid arthritis (RA). The aim of our study was to estimate its incidence in RA.
Methods:
We retrospectively reviewed complete blood (cell) count of patients with RA who received RTX between October 2007 and July 2011 to identify neutropenia (≤ 1.5 × 10(9)) up to 12 months following RTX.
Results:
One hundred eight patients received RTX, median age 64 years (range 25-86). A total of 237 cycles were given. Five patients developed LON after a median of 151 days (71-184). Two developed pneumonia.
Conclusion:
LON occurs infrequently after RTX, but can present with infection.
Related Concept Videos
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

